Alvotech

Alvotech is a biopharmaceutical company based in Reykjavík, Iceland, that specializes in the development, manufacturing, and commercialization of biosimilar medicines aimed at treating severe and chronic conditions. Founded in 2013, the company has expanded its operations to locations in Germany and Switzerland. Alvotech focuses on creating biosimilar versions of leading monoclonal antibodies, with six key molecules currently in development. The company is investing over $500 million in its product pipeline and has established partnerships with major global pharmaceutical firms to facilitate the commercialization of its offerings. Through its innovative approach, Alvotech aims to enhance patient access to effective treatments and improve overall health outcomes.